ClinicalTrials.gg
CompletedNCT05771090VAARAUpdated Jun 29, 2023

First Clinical Evaluation of a Novel Glucose Non-invasive Sensor Technology in Patients With Type 1 Diabetes

An interventional study of Sokru device in Diabetes Mellitus, sponsored by DCB Research AG. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-06-29.

Sponsored by DCB Research AG · Not applicable, Interventional, and Device feasibility

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Diabetes Mellitus with a site in Switzerland — 9 open to participants now, 11 under way, none of them phase 3. Diabetes Mellitus · Switzerland.

Enrollment
57th of 63
10 · median 141
Started
2023
with 6 others
No phase
31 of 87
4 open now
Registered
78th of 87
by date

Among the 87 studies in Diabetes Mellitus with a site in Switzerland, this one is the 57th largest by enrollment of the 63 interventional ones that give a count, is one of 7 that started in 2023, is one of 31 with no phase, and was the 78th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

9 of the 87 studies in Diabetes Mellitus with a site in Switzerland are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Diabetes Mellitus with a site in Switzerland, or all of them as a file.
02

Study summary

The primary aim of this clinical study is to find signal characteristics of VOCs detected by Sokru device during fasting, insulin injection and after glucose intake and to find the association with blood glucose variation in variant states of glycemia and hypoglycemia.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Volatile Organic Compounds
  • Hypoglycaemia
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • T1D with MDI or CSII therapy >1 year
  • Age 18 - 50 (inclusive)
  • Caucasian ethnicity
  • between 18.5 and 24.9 kg/m2 (inclusive)
  • Usage of a continuous glucose monitoring (CGM)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • History of cardiovascular diseases
  • Diabetes-related comorbidities
  • >9 %
  • Epilepsy
  • Known sensitivity to medical grade adhesives or other skin-related complications, which might influence the outcome
  • Known sensitivity to Latex
  • Participation in another investigation with an drug within the 30 days preceding and during the present investigation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Study arm

    Participants in the study arm will undergo the study procedure which are different induced glycaemic states.

    Device: Sokru device

Interventions

  • DeviceSokru device

    Different induced glycaemic states in people living with diabetes (PwD).

06

What researchers measure

Primary outcomes

  1. Characteristics of volatile organic compound (VOC) signals measured by the Sokru device

    The primary outcome are changes in VOC signals measured by the Sokru at low glucose levels (below 3.0 -3.9 mmol/L) or during the time when the blood glucose level is decreasing (from 10 and 3.9 mmol/L).

    Time frame: During the study procedure (approximately 5 hours)

Secondary outcomes

  1. Volatile Organic Compound Signals

    VOC signals measured by the Sokru device at different blood glucose levels

    Time frame: During the study procedure (approximately 5 hours)

  2. Blood glucose concentration

    Blood glucose levels are measured with the continuous glucose measurement system and in the venous blood at the time of the appearance of VOC signal peaks or drops

    Time frame: During the study procedure (approximately 5 hours)

  3. Time of onset of subjective symptoms of hypoglycemia

    Self-reported onset of subjective symptoms of hypoglycemia

    Time frame: During the study procedure (approximately 5 hours)

  4. Heart rate

    Heart rate is measured with a Mindray device

    Time frame: During the study procedure (approximately 5 hours)

  5. Oxygen saturation

    Oxygen saturation is measured with a Mindray device

    Time frame: During the study procedure (approximately 5 hours)

07

Study locations

1 site
  • Universitätsklinik für Diabetologie, Endokrinologie, Ernährungsmedizin & Metabolismus (UDEM) Inselspital, Universitätsspital
    Bern, 3010, Switzerland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jun 2023, 2 months.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 2 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2023
First posted
Mar 16, 2023
StartActual
Apr 1, 2023
Primary completionActual
Jun 16, 2023
CompletionActual
Jun 16, 2023
Last update
Jun 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05771090
Lead sponsor
DCB Research AG
Responsible party
Sponsor
First posted
Mar 16, 2023
Start date
Apr 1, 2023
Primary completion
Jun 16, 2023
Completion
Jun 16, 2023
Last update
Jun 29, 2023

Study contacts

Derek Brandt
study chair · DCB Research AG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion